SE0401066D0 - Chemical Derivatives - Google Patents

Chemical Derivatives

Info

Publication number
SE0401066D0
SE0401066D0 SE0401066A SE0401066A SE0401066D0 SE 0401066 D0 SE0401066 D0 SE 0401066D0 SE 0401066 A SE0401066 A SE 0401066A SE 0401066 A SE0401066 A SE 0401066A SE 0401066 D0 SE0401066 D0 SE 0401066D0
Authority
SE
Sweden
Prior art keywords
diagnosis
anthracycline derivatives
radiolabelled
delivery system
drug delivery
Prior art date
Application number
SE0401066A
Other languages
English (en)
Inventor
Stefan Sjoeberg
Katarina Edwards
Joergen Carlsson
Lars Gedda
Original Assignee
Stefan Sjoeberg
Katarina Edwards
Joergen Carlsson
Lars Gedda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Sjoeberg, Katarina Edwards, Joergen Carlsson, Lars Gedda filed Critical Stefan Sjoeberg
Priority to SE0401066A priority Critical patent/SE0401066D0/sv
Publication of SE0401066D0 publication Critical patent/SE0401066D0/sv
Priority to CNA2005800124959A priority patent/CN1956992A/zh
Priority to AT05733719T priority patent/ATE499378T1/de
Priority to EP05733719A priority patent/EP1740599B1/en
Priority to BRPI0510062-3A priority patent/BRPI0510062A/pt
Priority to JP2007509425A priority patent/JP5156372B2/ja
Priority to ES05733719T priority patent/ES2360708T3/es
Priority to US11/578,159 priority patent/US20070258890A1/en
Priority to DE602005026510T priority patent/DE602005026510D1/de
Priority to PCT/SE2005/000596 priority patent/WO2005103065A1/en
Priority to US12/578,380 priority patent/US8609135B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0401066A 2004-04-22 2004-04-22 Chemical Derivatives SE0401066D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE0401066A SE0401066D0 (sv) 2004-04-22 2004-04-22 Chemical Derivatives
PCT/SE2005/000596 WO2005103065A1 (en) 2004-04-22 2005-04-22 Anthracycline derivatives
BRPI0510062-3A BRPI0510062A (pt) 2004-04-22 2005-04-22 derivados de antraciclina
AT05733719T ATE499378T1 (de) 2004-04-22 2005-04-22 Anthracyclinderivate
EP05733719A EP1740599B1 (en) 2004-04-22 2005-04-22 Anthracycline derivatives
CNA2005800124959A CN1956992A (zh) 2004-04-22 2005-04-22 蒽环类抗生素衍生物
JP2007509425A JP5156372B2 (ja) 2004-04-22 2005-04-22 アントラサイクリン誘導体
ES05733719T ES2360708T3 (es) 2004-04-22 2005-04-22 Derivados de antraciclina.
US11/578,159 US20070258890A1 (en) 2004-04-22 2005-04-22 Anthracycline Derivatives
DE602005026510T DE602005026510D1 (en) 2004-04-22 2005-04-22 Anthracyclinderivate
US12/578,380 US8609135B2 (en) 2004-04-22 2009-10-13 Anthracycline derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401066A SE0401066D0 (sv) 2004-04-22 2004-04-22 Chemical Derivatives

Publications (1)

Publication Number Publication Date
SE0401066D0 true SE0401066D0 (sv) 2004-04-22

Family

ID=32322666

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401066A SE0401066D0 (sv) 2004-04-22 2004-04-22 Chemical Derivatives

Country Status (10)

Country Link
US (2) US20070258890A1 (sv)
EP (1) EP1740599B1 (sv)
JP (1) JP5156372B2 (sv)
CN (1) CN1956992A (sv)
AT (1) ATE499378T1 (sv)
BR (1) BRPI0510062A (sv)
DE (1) DE602005026510D1 (sv)
ES (1) ES2360708T3 (sv)
SE (1) SE0401066D0 (sv)
WO (1) WO2005103065A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794555A1 (en) * 2010-04-01 2011-10-06 Oncorena Ab Improved treatment of renal cell carcinoma
CN102086219A (zh) * 2010-11-24 2011-06-08 河南师范大学 具有抗癌活性的蒽环类抗生素简单结构类似物及制备方法
CN102146107B (zh) * 2011-01-14 2014-12-31 河南师范大学 (s)-2-羟烷基-1,4-二羟基-9,10-蒽醌与糖基缀合物的合成及抗肿瘤活性
CN113750047A (zh) * 2020-05-28 2021-12-07 浙江大学 多功能纳米脂质体、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS539756A (en) * 1976-07-14 1978-01-28 Microbial Chem Res Found Antitumers
US4177264A (en) * 1977-10-17 1979-12-04 Sri International N-benzyl anthracyclines
GB2007645B (en) * 1977-10-17 1982-05-12 Stanford Res Inst Int Benzyl anthracyclines and pharmaceutical compositions containing them
US4250303A (en) * 1977-10-17 1981-02-10 Sri International N-Benzyl anthracyclines
CA1248944A (en) * 1982-09-28 1989-01-17 Gareth J. Thomas Anthracycline glycosides
US4610977A (en) * 1985-04-08 1986-09-09 The University Of Tennessee Research Corporation N-alkyl and N-benzyl adriamycin derivatives
DE3641833A1 (de) * 1986-12-08 1988-06-09 Behringwerke Ag Zytostatisch wirksame anthracyclinderivate
DE3886155T2 (de) * 1987-09-25 1994-04-07 Zaidan Hojin Biseibutsu Anthracyclin-Derivate mit Inhibitorwirkung gegen die reverse Transkriptase des menschlichen Immundefizienzvirus.
US5874412A (en) * 1996-03-22 1999-02-23 Priebe; Waldemar Bis-anthracyclines with high activity against doxorubicin resistant tumors
WO2000056267A2 (en) * 1999-03-19 2000-09-28 Waldemar Priebe Methods and compositions for the manufacture of c-3' and c-4' anthracycline antibiotics
WO2003057687A1 (en) * 2001-12-27 2003-07-17 Albany Molecular Research, Inc. Methods for preparing doxorubicin derivatives

Also Published As

Publication number Publication date
EP1740599A1 (en) 2007-01-10
CN1956992A (zh) 2007-05-02
EP1740599B1 (en) 2011-02-23
DE602005026510D1 (en) 2011-04-07
US8609135B2 (en) 2013-12-17
US20100092388A1 (en) 2010-04-15
WO2005103065A1 (en) 2005-11-03
ES2360708T3 (es) 2011-06-08
BRPI0510062A (pt) 2007-10-16
US20070258890A1 (en) 2007-11-08
JP2007533736A (ja) 2007-11-22
JP5156372B2 (ja) 2013-03-06
ATE499378T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
RS52956B (en) CANCER TREATMENT COMPOSITIONS
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
MX2007006557A (es) Metodos para utilizar intratecalmente una formulacion de temozolomida en el tratamiento de canceres.
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
WO2005113720A3 (en) A strategy for designing patient-specific anti-cancer drugs
BRPI0510062A (pt) derivados de antraciclina
WO2008039525A3 (en) Cadherin antagonists in combination with anticancer agents for use in cancer treatment
BRPI0810682A2 (pt) agente antitumoral em especial para o tratamento de tumores dérmicos, fármaco, kit compreendendo fármaco.
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
RU2006122136A (ru) Способ комбинированного лечения местно-распространенных форм рака шейки матки
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
WO2009140572A3 (en) Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7
RU99103901A (ru) Способ медикаментозного лечения злокачественных опухолей
SI2091919T1 (sl) Derivati 18-amino substituiranih analogov geldamicin-hidrokinona s citotoksiäśno aktivnostjo za zdravljenje raka